Sun Allies With AZ To Drive China Oncology Push
Executive SummaryIndia's Sun Pharma joins hands with AstraZeneca to commercialize certain 'ready to use' oncology therapies in China, hoping to capitalize on the UK firm’s strong position in this market.
You may also be interested in...
Widely viewed as the largest fast-growing pharma market, China can nevertheless be hard to crack for small to mid-sized companies. But a new policy emphasis on quality and affordability are providing a rare opening for those with the right product mix and local partnerships in hand.
UK pharma giant’s head, International tells Scrip expanded alliance with diversified Japan group will develop solutions across the patient journey, while new China investments aim to tap into emerging innovation in this market.
Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.